CDI Labs’ Post

Molecular Profiling in Neuro-Oncology: Where We Are, Where We're Heading, and How We Ensure Everyone Can Come Along | American Society of Clinical Oncology Educational Book (ascopubs.org)

🌍 On Lung Cancer Awareness Month, let's reflect on the importance of raising awareness and supporting research in this area. Lung cancer remains one of the leading causes of death worldwide. 🔬 HAWK Biosystems is committed to research and exploring more precise ways to approach immunotherapy, with the potential to significantly improve responses and survival. 🌟 These advancements aim not only to enhance the treatment landscape but also to optimize investments for more effective outcomes. 🔍 Current research could change the game in the fight against lung cancer, offering hope to those battling this disease. 🏥 Very soon our technology will contribute to this advancement in lung cancer treatment. Read more: https://lnkd.in/eJpGCmz4 Together, we move towards a future with better responses to lung cancer. Join the fight!

Shortage of oncologists is a reality, not a forecast: 2022 Snapshot: State of the Oncology Workforce in America | JCO Oncology Practice (ascopubs.org) I am one of the 21% oncologists who left practice between 2015-2022. Without knowing, I was part of the problem, not the solution. Profile of the Oncology Physician Workforce and the Characteristics of Attrition | JCO Oncology Practice (ascopubs.org) We need to secure a robust oncology workforce to care for an increasing number of patients, as the population ages and the number of cancer survivors increase. How? Oncologists are leaving practices for several reasons, but burnout, hospital mergers, and monopoly of working conditions are key. Rural community practices are particularly affected. Pandemic didn't help either. To retain oncologists in rural communities, think about hybrid academic-community training programs: Training Hematologists/Oncologists for the Academic-Community Hybrid: Creating a Fellowship Framework for the Future | JCO Oncology Practice (ascopubs.org). Most importantly: oncologists, like other healthcare professionals, have to break the shackles from hospital conglomerates and be able to negotiate contracts that include salary, quality of care versus quantity, and better work life-balance. Otherwise, more cases like me will follow. And belive me, I am happier now than in my previous academic position.

Springer Healthcare's official partnership with #ASCO is one of my favourite things about working here. Official ASCO content + Springer-led expert commentary is one of the things our learners value about our accredited programs. AND it means both Springer Nature and ASCO can co-market to reach both our audiences #CME #IME #NSCLC #oncology #meded #medicaleducation #independentmedicaleducation #SpringerHealthcareIME

We are thrilled to share a recording of a GlycoNet webinar featuring Dr. Paula Videira, Co-Founder of CellmAbs, Co-director of GLYCOTwinning, and Associate Professor at Faculdade de Ciências e Tecnologia da Universidade NOVA de Lisboa. Introduced by Mr. David Firer, Chair of the GlycoNet Trainee Association – Executive Committee, Dr. Videira dives deep into "Unlocking the Glycoimmune Potential: Novel Strategies for Advanced Immunotherapy". Additionally, don’t miss the insightful presentation by her PhD student, Ms. Rita Adubeiro Lourenço, on "Deciphering the Enigmatic Role of O-glycan Signatures in Cancer". 👉 Watch the full recording here: https://lnkd.in/drFNUuS2 Learn more about GlycoNet and GLYCOTwinning and join us in advancing the field of glycomics and immunotherapy. #GlycoNet #GLYCOTwinning #Glycomics #glycobiology #CancerResearch #Glycoscience #Webinar

Cereno Scientific’s innovative study design of the Phase II study of CS1 in PAH published in the renowned medical journal Pulmonary Circulation.   The research article describes how the design of clinical trials is important to fully understand the mechanisms and benefits of new treatments. Numerous potential pharmacological treatments for PAH have shown promise in preclinical models but have failed to show clinical benefit in humans or have been associated with poor safety and tolerability. A novel feature of the CS1 Phase II study is that the patients are monitored for pulmonary hemodynamics and right heart ventricle function on a daily basis with the implanted CardioMEMS HF technology. Furthermore, in the study, which has safety and tolerability as primary objective, a wide array of functional, hemodynamic, and structural measures and biomarkers as well as patient-reported outcomes are being collected to provide an insight into not only the treatment effects but the disease progression itself. The research article concludes that CS1 represents a potential novel disease-modifying treatment for PAH.   Read the full press release via link.

Cereno Scientific’s innovative drug candidate CS585 featured as one of the future antiplatelet strategies in the top-tier Journal of Thrombosis and Haemostasis.  A review article titled “Antiplatelet strategies: past, present, and future” highlighted the company's innovative drug candidate CS585 as a promising future strategy in reducing platelet activity. The review article published in the prestigious Journal of Thrombosis and Haemostasis (JTH) 20th anniversary issue in December further states that antiplatelet therapy plays a critical role in the prevention and treatment of major cardiovascular diseases triggered by thrombosis. Read more via link.

We recently co-hosted an enlightening panel discussion with GenomeWeb, titled "PGx Testing Developments and Future Directions," featuring industry luminaries Dr. Vicky Pratt, past president of AMP; Dr. Bronwyn Ramey, Director of Precision Medicine at LetsGetChecked; and Glenn Sawyer, Associate Director for Clinical Genetics at Agena Bioscience. This panel delved deep into the evolving landscape of Pharmacogenomics (PGx) testing and its pivotal role in shaping the future of precision medicine. Here are three key takeaways: 1. PGx has made great advancements benefiting healthcare, particularly in the areas of chemotherapy drug toxicity profiling (DPYD) and psychotropics (anxiety and depression). 2. Significant challenges remain that slow the widespread adoption of PGx, including reimbursement and clinician/physician awareness and education as to the benefits of PGx testing. 3. The field of PGx is rapidly advancing and shows great promise for reducing adverse drug events and improving patient safety, particularly in the areas of cardiac, oncology and pain management drug selection, dosing, and treatments. If you missed the live session, don't worry! Watch the replay here: https://lnkd.in/gsjHYBWH #PrecisionMedicine #PGxTesting #Webinar #HealthcareInnovation #Pharmacogenomics #PGx

https://lnkd.in/eMR8YV74 Incredible paper - thank you to the authors who published this. I still find it challenging determining the optimal use of adjuvant pembro in TNBC. What do you do in your practice?

View the role of molecular characteristics in guiding treatment selection and clinical trial enrollment | 0.5-hour CME/CE | Video Activity #2 of 3 in the LGSOC Library #PRIME #CME #MedEd #ovariancancer https://bit.ly/3D7w79Z